Dear Cancer: New Tests, New Treatments, and New Hope

Out of Patients with Matthew Zachary

The presenting sponsor for today's episode is Elevation Oncology, elevating precision medicine to the forefront of every cancer treatment journey. On the show today, I welcome the esteemed Dr. Stephen Liu, Associate Professor of Medicine, Director of Thoracic Oncology, and Director of Developmental Therapeutics at Lombardi Comprehensive Cancer Center of Georgetown University. At a time when cancer treatment is more about your DNA and your RNA than where in your body cancer is — it's more important than ever to continue elevating the conversation about making biomarker testing a mandatory part of care. Why napalm everything if your genes make you eligible for a specific kind of therapy that's wayyyy better than proverbial napalm? NRG1 Fusion is an RNA test done on solid tumors — for the purposes of this episode Lung Cancer tumors — but this is a test that everyone with lung cancer needs to get out of the gate. You enter the "I have lung cancer store" and — BOOM — you get this test, which can make or break the trajectory of your care. From the seriousness of Phase II enrollment challenges to inane musings about Dartmouth, Boston Market, and the children's book The Three Billy Goats Gruff, strap in for a serious discussion about precision oncology and biomarker testing, especially if you or someone you know has lung cancer. For more information visit https://nrg1fusion.com/pod.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.